ACTIVE

PROGRESS PHARMA

Financial year 2025 · Closed on 31/12/2025

Net result-5,5 k €-87,6 %over 1 year

Gross margin-4,9 k €-108,1 %over 1 year

Equity47,1 k €-49,1 %over 1 year

Identity

Source · BCE/KBO

PROGRESS PHARMA is a Public limited company incorporated in 2013. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Vosselaar.

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0536.258.560
Incorporation: 27/06/2013
Legal form: Public limited company
Registered office: Roekendreef 14
2350 Vosselaar · FlandreSee on map
Contributed capital: 61 500,00 €
Latest accounts: 31/12/2025

Activities (NACE)

72109Research and experimental development on natural sciences and engineering· main 72190Other research and experimental development on natural sciences and engineering 82990Other business support service activities n.e.c.82990Other business support service activities n.e.c.

Signals

Solid equityLow riskGood liquidity

Financials

Source · NBB, 12 filings

Trend over 12 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	-4,9 k €	-108%	-2,4 k €	-100%	-1,2 k €	-24.7%	-940,7 €	+44.3%	-1,7 k €
EBITDA	-5,4 k €	-89.5%	-2,9 k €	-71.4%	-1,7 k €	-19.9%	-1,4 k €	+34.9%	-2,1 k €
Operating result	-5,4 k €	-89.5%	-2,9 k €	-71.4%	-1,7 k €	-19.9%	-1,4 k €	+34.9%	-2,1 k €
Net result	-5,5 k €	-87.6%	-2,9 k €	-64.6%	-1,8 k €	-26.6%	-1,4 k €	+36.3%	-2,2 k €
Balance sheet
Equity	47,1 k €	-49.1%	92,6 k €	-3.1%	95,5 k €	-1.8%	97,3 k €	-1.4%	98,7 k €
Total assets	49,9 k €	-46.9%	94 k €	-2.7%	96,6 k €	-1.2%	97,8 k €	-1.9%	99,7 k €
Cash	18,1 k €	-70.9%	62,2 k €	-4.0%	64,8 k €	-1.8%	66 k €	-2.7%	67,9 k €
Debts	2,8 k €	+95.3%	1,4 k €	+29.0%	1,1 k €	+107%	536,2 €	-46.2%	996,3 €

Valuation

Indicative valuation

As an indication, this company is worth

between 0 € and 100 k€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 6 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
CONCORDE CONSULTING0810.645.826Represented by Dirk Van Broekhoven	Directorsince 27/06/2013
Luc Lammens	Directorsince 27/06/2013
R&S Consulting0886.139.243Represented by Dirk Reyn	Chairman of the board of directorssince 27/06/2013Director27/06/2013 → 2015 accountsended
SIMBIOSIS.LIFE0818.008.225Represented by Marina Cools	Directorsince 27/06/2013
SALVEGEN HEALTHCARE BVRepresented by Emilius VAN DONGEN	Managing director

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
ESMA BVRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2020 accounts
Luc Lemmens	Director13/05/2019 → 2022 accounts
Salvegan Healthcare LTDRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2022 accounts
Salvegen Healthcare LtdRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2021 accounts

Other companies at this address

Roekendreef 14 2350 Vosselaar

Company	CBE no.
R&S Consulting● Active	0886.139.243

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Micro model	Micro model	Micro model	Micro model	Micro model	Micro model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	05/06/2026	16/05/2025	27/06/2024	20/06/2023	04/07/2022	28/06/2021
General meeting	29/05/2026	08/05/2025	12/06/2024	07/06/2023	08/06/2022	23/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 12 filings

Model	Closing	General meeting	Filed	Language	Document
Micro model	31/12/2025	29/05/2026	05/06/2026	Dutch	PDF
Micro model	31/12/2024	08/05/2025	16/05/2025	Dutch	PDF
Micro model	31/12/2023	12/06/2024	27/06/2024	Dutch	PDF
Micro model	31/12/2022	07/06/2023	20/06/2023	Dutch	PDF
Micro model	31/12/2021	08/06/2022	04/07/2022	Dutch	PDF
Micro model	31/12/2020	23/06/2021	28/06/2021	Dutch	PDF
Micro model	31/12/2019	08/06/2020	30/06/2020	Dutch	PDF
Micro model	31/12/2018	13/05/2019	21/06/2019	Dutch	PDF
Micro model	31/12/2017	10/05/2018	25/06/2018	Dutch	PDF
Abridged model	31/12/2016	11/05/2017	23/05/2017	Dutch	PDF
Abridged model	31/12/2015	23/05/2016	17/06/2016	Dutch	PDF
Abridged model	31/12/2014	15/05/2015	17/06/2015	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 0 € and 100 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 6 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
CONCORDE CONSULTING0810.645.826Represented by Dirk Van Broekhoven	Directorsince 27/06/2013
Luc Lammens	Directorsince 27/06/2013
R&S Consulting0886.139.243Represented by Dirk Reyn	Chairman of the board of directorssince 27/06/2013Director27/06/2013 → 2015 accountsended
SIMBIOSIS.LIFE0818.008.225Represented by Marina Cools	Directorsince 27/06/2013
SALVEGEN HEALTHCARE BVRepresented by Emilius VAN DONGEN	Managing director

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
ESMA BVRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2020 accounts
Luc Lemmens	Director13/05/2019 → 2022 accounts
Salvegan Healthcare LTDRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2022 accounts
Salvegen Healthcare LtdRepresented by Emilius Van Dongen	Managing director13/05/2019 → 2021 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates06/01/2026
KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF
Mandates10/10/2024
ONTSLAGEN - BENOEMINGEN
PDF
Mandates06/04/2020
KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates15/12/2016
Ontslag & benoeming bestuurder ;
PDF
Registered office03/04/2015
Wijziging van de maatschappelijke zetel
PDF
Other10/07/2013
OPRICHTING
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings12 filings

Mandates

CONCORDE CONSULTING

SIMBIOSIS.LIFE

R&S Consulting

SALVEGEN HEALTHCARE BV

Luc Lammens

ESMA BV

Salvegan Healthcare LTD

Salvegen Healthcare Ltd

Luc Lemmens

EMSA BV

EMSA B.V. BO

20132014201520162017201820192020202120222023202420252026

PROGRESS PHARMA

Roekendreef 14, 2350 Vosselaar

Director

Chairman of the board of directorsDirector

Managing director

Director

Managing director

Director

DirectorManaging director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Roekendreef 14, 2350 VosselaarCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00144919

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
PROGRESS PHARMACurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00144919

Events

2025
Annual accounts 2025-5,5 k €↓
2024
Annual accounts 2024-2,9 k €↓
2023
Annual accounts 2023-1,8 k €↓
2022
Annual accounts 2022-1,4 k €↑
2021
Annual accounts 2021-2,2 k €↑
2020
Annual accounts 2020-6,3 k €↑
2019
Annual accounts 2019-7,2 k €↑
2018
Annual accounts 2018-8,1 k €↑
2017
Annual accounts 2017-9,8 k €↑
2016
Annual accounts 2016-69,8 k €↓
2015
Annual accounts 201547,5 k €↑
2014
Annual accounts 2014-345,3 k €
27/06/2013
IncorporationPublic limited company

PROGRESS PHARMA

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events